CA-TRANSPHORM-INC
17.12.2019 14:02:09 CET | Business Wire | Press release
Transphorm Inc. —the leader in the design and manufacturing of the highest reliability and first JEDEC and AEC-Q101 qualified high voltage gallium nitride (GaN) power semiconductors—today confirmed that customer AES Aircraft Elektro/Elektronik System GmbH has released its first 650 V GaN-based power supplies. Serving the aviation industry, AES supports customers with various products and services ranging from electrical engineering to certification and testing. The company’s newest Switch Mode Power Supplies are currently used by large CS-25 airplane manufacturers (e.g., Airbus A318-A321, A330, A340, A380 and Boeing B767, B787 VIP aircraft) and use Transphorm’s GaN FETs to increase overall system efficiency by more than 10 percent compared to competitive Silicon-based power supply units (PSUs).
The two GaN-based Switch Mode Power Supplies are the PS250X 500 W system and the PS6120 1200 W system . Both products support a 96-130 VAC/360 Hz – 800 Hz input voltage with a 28 VDC continuous power output at 15 amps for the 500 W system and 42 amps for the 1200 W system.
Further, AES certified the PS250X and PS6120 as DO-160 compliant—meeting the more than 25-point stringent Standard of the Radio Technical Commission for Aeronautics (RTCA). This Standard assesses system impact and performance under various external and internal conditions on aircraft—ranging from pressure and temperature to voltage spikes and RF emissions.
The flagship 500 W PS250X is the industry’s first passively cooled power supply at 420 W and deploys Transphorm’s GaN in a single-phase CCM boost power factor correction (PFC) topology. It offers more than 92 percent overall system efficiency at full load, which is more than 10 percent greater than its competition. The system also yields a more than .98 power factor and 200 mVpp nominal at 115 VAC/400 Hz input at full load. All within an end product that is 1.4 kg (~3 lbs).
The 1200 W PS6120 deploys Transphorm’s GaN in a fan-cooled, three-phase CCM boost PFC topology. It offers more than 91.5 percent overall system efficiency at full load, which is 11.5 percent greater than its competition. The PS6120 also yields the same power factor and nominal ripple voltage at 115 VAC/400 Hz input at full load as the PS250X 500 W PSU. All within an end product that is 4.0 kg (~8.8 lbs).
“The aviation industry is working toward reducing climate impact through any means possible,” said Dr. Andreas Hammer, Head of Competence Center Power, AES. “Considering, we sought out Transphorm’s GaN to replace previously used Silicon MOSFETs so that we could provide a more efficient, lighter weight power supply. These supplies have the potential to make a notable impact when considering each aircraft deploys several such PSUs. After only a year of redesign, we were able to offer our customers a better power solution, while also raising the performance bar within our own industry.”
The GaN Selection Process
Interested in the technology’s inherent higher switching frequency, AES reviewed GaN power switch converters from several GaN device semiconductor manufacturers. The company ultimately selected Transphorm’s 650 V GaN technology due primarily to its ease of drivability and designability—specifically because Transphorm’s GaN FETs do not require custom drivers. As a result, system design is simplified while engineers can drive the switches using technology they are already familiar with (i.e., drivers and packages). Other factors affecting AES’ selection included Transphorm’s proven reliability—which is underscored by its GaN platform earning both a JEDEC qualification and AEC-Q101 qualification at 175°C.
“Transphorm designed its GaN devices to enable designers, not challenge them,” said Philip Zuk, VP of Worldwide Technical Marketing and NA Sales, Transphorm, “Our two-switch normally-off GaN devices come in standard packages and require minimal supporting circuitry to drive them, which reduces the overall system size, increases reliability, and simplifies design. It’s crucial to us that our customers can come to market quickly with a product they have confidence in. We’re honored to be AES’ GaN supplier of record and are proud that they appreciate the work we’ve done to bring the benefits of GaN technology to the masses.”
AES’ PS250X and PS6120 power supplies are currently shipping.
About AES
Headquartered in Germany, AES Aircraft Elektro/Elektronik System GmbH is an international company comprised of over 160 highly skilled employees, serving customers in the aviation, space, and maritime industries. AES’ portfolio includes, but is not limited to, aircraft cabins electronics, comprehensive electrical engineering services, electronic design, and certification services.
About Transphorm
Transphorm designs and manufactures the highest performance, highest reliability 650 V and 900 V GaN semiconductors for high-voltage power applications. Holding the largest IP portfolio (1000+ patents), Transphorm produces the industry’s first JEDEC and only AEC-Q101 qualified GaN FETs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191217005252/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
